Total Payments
$1.9M
2024 Payments
$211,030
Companies
89
Transactions
3,347
Medicare Patients
4,977
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$1.4M (76.0%)
Travel$256,115 (13.7%)
Consulting$139,555 (7.5%)
Food & Beverage$54,139 (2.9%)
Education$284.79 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 464 | 73.4% |
| Travel and Lodging | $256,115 | 1,081 | 13.7% |
| Consulting Fee | $139,555 | 96 | 7.5% |
| Food and Beverage | $54,139 | 1,658 | 2.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $31,636 | 12 | 1.7% |
| Honoraria | $8,405 | 10 | 0.4% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $6,464 | 4 | 0.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $750.00 | 1 | 0.0% |
| Long term medical supply or device loan | $398.80 | 4 | 0.0% |
| Education | $284.79 | 16 | 0.0% |
| Grant | $250.00 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $680,768 | 1,069 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $296,395 | 307 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $154,653 | 236 | $0 (2024) |
| Celgene Corporation | $126,985 | 135 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $125,986 | 235 | $0 (2024) |
| Genentech USA, Inc. | $97,182 | 211 | $0 (2024) |
| SOBI, INC | $83,622 | 57 | $0 (2024) |
| Daiichi Sankyo Inc. | $64,394 | 99 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $54,227 | 63 | $0 (2024) |
| GlaxoSmithKline, LLC. | $53,699 | 60 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $211,030 | 363 | SOBI, INC ($83,572) |
| 2023 | $255,254 | 439 | TAIHO ONCOLOGY, INC. ($85,444) |
| 2022 | $322,418 | 486 | E.R. Squibb & Sons, L.L.C. ($104,070) |
| 2021 | $275,959 | 452 | Incyte Corporation ($93,717) |
| 2020 | $128,152 | 217 | Incyte Corporation ($48,144) |
| 2019 | $239,101 | 457 | Incyte Corporation ($120,892) |
| 2018 | $196,855 | 460 | Incyte Corporation ($114,964) |
| 2017 | $243,884 | 473 | Incyte Corporation ($104,059) |
All Payment Transactions
3,347 individual payment records from CMS Open Payments — Page 1 of 134
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $39.73 | General |
| Category: Oncology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $458.63 | General |
| Category: Hematology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $253.12 | General |
| Category: Hematology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $129.82 | General |
| Category: Hematology | ||||||
| 12/18/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $23.90 | General |
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $3.11 | General |
| Category: Oncology | ||||||
| 12/16/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $26.90 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,080.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $631.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $278.82 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $140.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | Cash or cash equivalent | $137.42 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | Cash or cash equivalent | $55.21 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,080.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $22.59 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $28.10 | General |
| Category: Oncology | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $19.97 | General |
| Category: Hematology | ||||||
| 12/05/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $5.00 | General |
| Category: Hematology | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,541.00 | General |
| Category: Hematology | ||||||
| 11/27/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,235.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,063 | 28,770 | $383,217 | $147,445 |
| 2022 | 27 | 1,066 | 10,094 | $460,338 | $216,886 |
| 2021 | 35 | 1,507 | 42,678 | $843,872 | $352,095 |
| 2020 | 29 | 1,341 | 19,287 | $719,274 | $302,277 |
Total Patients
4,977
Total Services
100,829
Medicare Billing
$1.0M
Procedure Codes
116
All Medicare Procedures & Services
116 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 278 | 597 | $74,625 | $36,726 | 49.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 53 | 275 | $69,300 | $26,214 | 37.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 18 | 22,500 | $67,500 | $19,531 | 28.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 162 | 195 | $15,445 | $7,543 | 48.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 35 | 289 | $17,340 | $6,330 | 36.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 43 | 128 | $15,232 | $6,022 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 45 | 62 | $11,284 | $5,956 | 52.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 34 | 50 | $9,150 | $4,900 | 53.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 48 | 67 | $8,442 | $4,521 | 53.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 45 | $7,965 | $4,136 | 51.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 56 | 56 | $10,360 | $4,038 | 39.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 72 | $9,000 | $3,544 | 39.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $8,680 | $3,494 | 40.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 136 | $7,616 | $2,941 | 38.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 21 | $7,203 | $2,813 | 39.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 45 | 230 | $17,940 | $2,419 | 13.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 28 | 180 | $7,200 | $2,108 | 29.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 60 | $5,400 | $1,428 | 26.4% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 17 | 150 | $3,000 | $1,021 | 34.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 11 | 49 | $1,813 | $772.23 | 42.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 740 | $4,440 | $603.41 | 13.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 18 | 1,614 | $1,614 | $157.90 | 9.8% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 23 | 122 | $244.00 | $99.81 | 40.9% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 14 | 1,064 | $2,128 | $79.83 | 3.8% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 11 | 37 | $296.00 | $46.99 | 15.9% |
About Dr. Jason Salganick, MD
Dr. Jason Salganick, MD is a Medical Oncology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124125174.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Salganick, MD has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $211,030 received in 2024. These payments were reported across 3,347 transactions from 89 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Salganick has provided services to 4,977 Medicare beneficiaries, totaling 100,829 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 116 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Phoenix, AZ
- Active Since 09/20/2006
- Last Updated 11/14/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1124125174
Products in Payments
- JAKAFI (Drug) $605,742
- INQOVI (Drug) $232,494
- REBLOZYL (Biological) $108,596
- Revlimid (Drug) $84,545
- VONJO (Drug) $83,447
- TECENTRIQ (Biological) $74,135
- LONSURF (Drug) $59,248
- ALUNBRIG (Drug) $55,627
- OJJAARA (Drug) $53,285
- LYNPARZA (Drug) $49,837
- Vonjo (Drug) $38,196
- Enhertu (Drug) $26,257
- ONUREG (Drug) $24,497
- FASLODEX (Drug) $21,061
- CALQUENCE (Drug) $18,576
- MONJUVI (Drug) $16,639
- Alecensa (Biological) $15,547
- IMFINZI (Biological) $15,026
- Pomalyst (Drug) $14,583
- ENHERTU (Biological) $14,558
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Phoenix
Mazen Khattab, Md, MD
Medical Oncology — Payments: $226,385
Medical Oncology $226,385
Panayiotis Savvides, Md, MD
Medical Oncology — Payments: $217,105
Medical Oncology $217,105
Amber Flaherty, M.d, M.D
Medical Oncology — Payments: $41,476
Medical Oncology $41,476
Tania Cortas, Md, MD
Medical Oncology — Payments: $36,718
Medical Oncology $36,718
Waqas Arslan, M.d, M.D
Medical Oncology — Payments: $34,523
Medical Oncology $34,523
Dr. Amir Azadi, M.d, M.D
Medical Oncology — Payments: $23,762
Medical Oncology $23,762